THE ADVANTAGES OF VACCIMAX®
A Novel Approach that Redefines a Familiar Platform
IVT's patented technology is based on a novel approach to the use of liposomes. While historically liposomes have contributed only marginally to the production of an immune response, IVT has discovered that liposomes stabilized by our VacciMax® technology significantly enhance antibody production. IVT has demonstrated that VacciMax® not only improves humoral response, but also cell-mediated response (cytotoxic CTL).
Flexible and Effective
• Can be used with any antigen, including recombinant proteins and synthetic peptide antigens, as well as antigens already used in commercial vaccines
• Elicits cell-mediated and humoral responses
• Creates higher level of antibodies, compared to conventional vaccine technology
• Single injection results can result in a long duration (in some cases multi-year) response.
Researchers in the field of immunology have commented to IVT staff that the longevity of this immune response has not been observed before in vaccine research. The VacciMax® vaccine platform provides five distinct advantages:
More rapid immune response following immunization, allowing quicker prophylactic protection of a population following disease outbreak.
Higher level of antibody titers, providing more effective and complete immune protection.
Higher proportion of antibodies which bind to intended target, providing greater efficacy, especially against difficult to target antigens. Antibodies are directed to 3-dimensional protein structures, resulting in more affinity to the native proteins.
Longer duration of immune response following single-administration, providing multi-year protection without boosters.
Safety profile, all the liposome components are proven safe.
The proprietary VacciMax® vaccine platform shows improved performance for human and veterinary vaccine applications.
